Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 996.80
Bid: 999.80
Ask: 1,000.50
Change: 11.20 (1.14%)
Spread: 0.70 (0.07%)
Open: 985.00
High: 1,006.00
Low: 984.20
Prev. Close: 985.60
SN. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Smith & Nephew to present today at JP Morgan

7 Jan 2019 07:00

RNS Number : 3008M
Smith & Nephew Plc
07 January 2019
 

 

Smith & Nephew to present today at J.P. Morgan Healthcare Conference

7 January 2019

Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, will participate in the 37th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel, San Francisco, California, USA.

 

Namal Nawana, Chief Executive Officer, will present today at 8.30am Pacific Time (4.30pm GMT) on Monday 7 January 2019, followed by a Question & Answer session at 9.00am.

 

Live webcasts of the presentation and Q&A will be accessible via the events section on the Smith & Nephew investor relations website. Transcripts of both will be available shortly thereafter.

 

There will be no update on trading during the presentation or Q&A. Smith & Nephew confirms that it expects to meet its 2018 full year guidance, as disclosed in its Third Quarter Trading Report on 1 November 2018, and will publish its fourth quarter and full year results for 2018 on 7 February 2019.

 

 

 

Enquiries

 

Investors

Andrew SwiftSmith & Nephew

+44 (0) 20 7960 2285

 

Media

Charles ReynoldsSmith & Nephew

+44 (0) 1923 477314

Ben Atwell / Andrew WardFTI Consulting

+44 (0) 20 3727 1000

About Smith & Nephew

Smith & Nephew is a portfolio medical technology business with leadership positions in Orthopaedics, Wound, Sports Medicine and ENT. Smith & Nephew has more than 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN). For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com and follow us on Twitter, LinkedIn or Facebook.

 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCCKPDNFBKKCDK
Date   Source Headline
9th Mar 20226:01 pmRNSDirector/PDMR Shareholding
8th Mar 20226:14 pmRNSTransaction in Own Shares
8th Mar 20224:00 pmRNSDirector/PDMR Shareholding
7th Mar 20226:21 pmRNSTransaction in Own Shares
7th Mar 20223:30 pmRNSAnnual Financial Report
4th Mar 20226:07 pmRNSTransaction in Own Shares
4th Mar 202210:16 amRNSDirector/PDMR Shareholding
3rd Mar 20226:09 pmRNSTransaction in Own Shares
2nd Mar 20225:57 pmRNSTransaction in Own Shares
1st Mar 20226:12 pmRNSTransaction in Own Shares
1st Mar 202212:11 pmRNSTotal Voting Rights
28th Feb 20226:06 pmRNSTransaction in Own Shares
25th Feb 20226:05 pmRNSTransaction in Own Shares
24th Feb 20226:11 pmRNSTransaction in Own Shares
23rd Feb 20226:18 pmRNSTransaction in Own Shares
23rd Feb 20229:00 amRNSDirector/PDMR Shareholding
22nd Feb 202212:30 pmRNSTransaction in Own Shares
22nd Feb 20227:01 amRNSSmith+Nephew announces new Chief Executive Officer
22nd Feb 20227:00 amRNSFinal Results
1st Feb 20224:30 pmRNSBlock listing Interim Review
1st Feb 20221:15 pmRNSTotal Voting Rights
25th Jan 202210:00 amRNSJo Hallas joins Smith+Nephew as NED
25th Jan 20229:00 amRNSNotice of Results
19th Jan 20225:00 pmRNSDirector/PDMR Shareholding
19th Jan 20227:00 amRNSS+N acquires novel cementless partial knee system
4th Jan 20221:12 pmRNSTotal Voting Rights
16th Dec 202112:00 pmRNSSmith+Nephew outlines ‘Strategy for Growth'
1st Dec 202112:08 pmRNSTotal Voting Rights
17th Nov 20212:00 pmRNSDirector/PDMR Shareholding
12th Nov 20214:30 pmRNSDirector/PDMR Shareholding
4th Nov 20217:00 amRNSTrading Statement
2nd Nov 202110:30 amRNSDirector/PDMR Shareholding
1st Nov 20213:00 pmRNSDirector/PDMR Shareholding
1st Nov 20211:53 pmRNSTotal Voting Rights
29th Oct 202111:45 amRNSDirector/PDMR Shareholding
22nd Oct 20219:00 amRNSSmith+Nephew to host Meet the Management event
15th Oct 20218:47 amRNSDividend Declaration
8th Oct 20219:00 amRNSNotice of Results
1st Oct 202110:16 amRNSTotal Voting Rights
24th Sep 20213:47 pmRNSDirector/PDMR Shareholding
17th Sep 20212:30 pmRNSAdditional Listing
16th Sep 20217:00 amRNSDirector/PDMR Shareholding
14th Sep 20215:00 pmRNSDirector/PDMR Shareholding
1st Sep 202110:59 amRNSTotal Voting Rights
27th Aug 20219:00 amRNSDirector/PDMR Shareholding
24th Aug 202110:30 amRNSDirector/PDMR Shareholding
23rd Aug 20211:00 pmRNSDirector/PDMR Shareholding
17th Aug 202111:15 amRNSDirector/PDMR Shareholding
4th Aug 202111:31 amRNSDirector/PDMR Shareholding
2nd Aug 20212:53 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.